20/08/2026
MSCAN is always very pleased when there's good news for the melanoma and skin cancer patient community! And today we're reporting news on an important clinical trial.
In summary, mRNA-based cancer therapy is an exciting space for clinical trials, melanoma and skin cancer.
And for the the longer version: Today, positive topline results were released from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (V940) in combination with Keytruda (pembrolizumab) as adjuvant treatment for patients with completely resected stage IIB–IV melanoma.
Intismeran autogene is an investigational mRNA-based individualised neoantigen therapy. It is specifically designed for an individual patient based on the unique set of mutations within that person's tumour. The goal is to train and activate the immune system to recognise and fight cancer.
This marks the first positive Phase 3 readout for an individualised neoantigen therapy and an mRNA-based cancer therapy. In the pre-specified interim analysis, the combination demonstrated statistically significant and clinically meaningful improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared with Keytruda alone.
Full data, including overall survival results, are still to come.